Summary
This white paper discusses how leading pharmaceutical companies are calculating the return on investment (ROI) for artificial intelligence (AI) in research and development (R&D). It outlines the significant investments being made in AI platforms to enhance drug discovery and development processes. The paper highlights the challenges faced by R&D leaders in articulating the tangible ROI from AI initiatives, often relying on operational metrics that may not accurately reflect enterprise-wide value. A proposed multidimensional ROI framework is presented, which aims to align AI investments with R&D objectives by integrating quantitative metrics across scientific, operational, and commercial dimensions. The document emphasizes the importance of embedding ethical considerations and explainability into AI governance to ensure sustainable and responsible AI-driven value. Additionally, it examines current practices in measuring AI ROI and the need for standardized methodologies to translate AI outputs into concrete business outcomes, ultimately advocating for a structured approach to capture AI's full potential in pharma R&D.
